Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Brightline Interactive appeals Nasdaq delisting notice over minimum bid price breach

Brightline Interactive appeals Nasdaq delisting notice over minimum bid price breach

BitgetBitget2026/09/18 12:51
  • Brightline Interactive requested a Nasdaq Hearings Panel hearing on Sept. 17, 2026 to appeal a delisting determination.
  • Nasdaq cited non-compliance with the $1 minimum bid price requirement under Listing Rule 5550(a)(2).
  • The hearing request triggers an automatic stay of any suspension or delisting pending the panel’s decision.
  • Brightline awaits a hearing date while working to regain compliance with Nasdaq continued listing standards.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brightline Interactive Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202609180850ACCESSWRNAPR_____1223447) on September 18, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

After Eli Lilly's nearly 300% surge in four years, Wall Street remains bullish: The "hidden pipeline" beyond GLP-1 is underestimated

Eli Lilly’s share price has surged nearly 300% since the approval of its first GLP-1 drug, with its market capitalization surpassing 1 trillion USD, yet Wall Street remains optimistic about its continued growth. Berenberg has upgraded Eli Lilly’s rating to “Buy," believing that Mounjaro and Zepbound will continue to see strong volume, and that the oral GLP-1 drug could further drive demand. Additionally, Eli Lilly continues to expand into areas such as cancer and sleep disorders, and the potential of its non-obesity-related pipelines remains underestimated by the market.

华尔街见闻2026/09/18 13:21

Goldman Sachs: The industrial sector is "even more expensive" than tech stocks; global sector pricing logic is changing

The 12-month forward price-to-earnings ratio of the industrial sector has now surpassed that of the technology sector, indicating that the relative valuations among various sectors in global stock markets are undergoing a shift.

智通财经2026/09/18 13:11